A5048797917- Heart Failure Treatment and Management
- Palliative Care and End-of-Life Issues
- Chemotherapy-induced cardiotoxicity and mitigation
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Pharmaceutical Practices and Patient Outcomes
- Cancer Treatment and Pharmacology
- Academic Writing and Publishing
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Health Sciences Research and Education
- Advanced Breast Cancer Therapies
- Cancer-related cognitive impairment studies
- Mechanical Circulatory Support Devices
- Signaling Pathways in Disease
- Innovations in Medical Education
- Peptidase Inhibition and Analysis
- Emergency and Acute Care Studies
- Chemotherapy-induced organ toxicity mitigation
- Medication Adherence and Compliance
- Histone Deacetylase Inhibitors Research
- Cardiac pacing and defibrillation studies
Albert Einstein College of Medicine
2023-2025
Montefiore Medical Center
2023-2024
University of Chicago
2018-2022
Stony Brook University
2016
Background Cardiotoxicity in patients with cancer treated anthracyclines is associated increased morbidity and mortality. We aimed to examine the incidence of risk factors for cardiotoxicity a racially ethnically diverse cohort anthracyclines. Methods included consecutive adult who underwent anthracycline‐based chemotherapy from 2016 2019 any type cancer. The end point was development (defined as clinical heart failure or drop left ventricular ejection fraction ≥10% ≤50%). Results A total...
Lack of absolute selectivity against cancer cells is a major limitation for current therapies.In the previous study, we developed prodrug strategy selective therapy using masked cytotoxic agent puromycin [Boc-Lys(Ac)-Puromycin], which can be sequentially activated by histone deacetylases (HDACs) and cathepsin L (CTSL) to kill expressing high levels both enzymes.Despite promise as therapy, its requirement relatively dosage could potential issue in clinical setting.To address this issue, aimed...
Background: Older adults with cancer use the emergency department (ED) for acute concerns. Objectives: Characterize palliative care needs and clinical outcomes of advanced patients in ED. Design: A planned secondary data analysis Comprehensive Oncologic Emergencies Research Network (CONCERN) data. Settings/Subjects: Cancer who presented to 18 CONCERN affiliated EDs United States. Measurements: Survey included demographics, type, functional status, symptom burden, hospice enrollment, advance...
Emergency department (ED) visits by patients with cancer frequently end in hospitalization. As concerns about ED and hospital crowding increase, observation unit care may be an important strategy to deliver safe efficient treatment for eligible patients. In this investigation, we compared the prevalence clinical characteristics of who received those were admitted from ED.We performed a multicenter prospective cohort study presenting affiliated one 18 hospitals Comprehensive Oncologic...
Introduction: There are limited data on anthracycline cardiotoxicity in racially and ethnically diverse populations. Aims: Our study sought to examine the incidence of changes left ventricular ejection fraction (LVEF) cancer survivors treated with a multiracial/ethnic community. Methods: We included consecutive adult patients who underwent anthracycline-based chemotherapy from 2016 2019 for any type cancer. Patients preexisting heart failure were excluded. The endpoint was development...
Introduction: There are sparse data on the impact of socioeconomic status (SES) incidence anthracycline cardiotoxicity. Aims: To examine association neighborhood-level SES factors with Methods: We included consecutive adult patients who underwent anthracycline-based chemotherapy from 2016 to 2019 for any type cancer in Montefiore Health System. The endpoint was development cardiotoxicity (defined as clinical heart failure or drop left ventricular ejection fraction [LVEF]≥10% LVEF<53%)....